Skip to main content
ABCLAbCellera Biologics Inc.Sell5.4·$11.12
SellModerate Confidence
Investment thesis

AbCellera is a cash-burning biotech with collapsing revenue and weak quality, offset by 40% analyst upside, modest insider buying and a reward-to-risk of 1.59.

Thesis pillars

  • Collapsing Revenue Value Trap↓Deteriorating
  • Cash Burn Weak Quality→Stable
  • Analyst Upside Reward To Risk↑Improving
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 1, 2026, based on the 10-K filed Feb 24, 2026

Full reasoning →

Open full analysis

AbCellera Biologics Inc. (ABCL) Stock Analysis

SellVALUE-TRAP 1/5QualityShortModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $11.12: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 1.56; Below-average business quality.

AbCellera Biologics is a clinical-stage biotechnology company developing antibody medicines, with two internal candidates in clinical trials - ABCL635 for vasomotor symptoms and ABCL575 for atopic dermatitis - alongside a portfolio of royalty and milestone stakes from more than... Read more

$11.12+46.0% A.UpsideScore 5.4/10#99 of 240 Biotechnology
QualityF-score3 / 9FCF yield-1.28%
Stop $10.44Analyst target $16.24(−13% haircut)A.R:R 3.1:1
Analyst consensus$18.67+67.9%12 analysts with price targets
$16.24Analyst target
$11.12price
$18.67mean
$30

Sell if holding. Engine safety override at $11.12: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 1.56; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news boost analyst 0.50, earnings proximity 98d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.

10-K grounded · weekly refresh

About AbCellera Biologics Inc.

About AbCellera Biologics Inc.

AbCellera Biologics, based in Vancouver, Canada, has two antibody drug candidates in clinical trials: ABCL635, a Phase 1/2 non-hormonal treatment for menopausal vasomotor symptoms with topline data expected in the third quarter of 2026, and ABCL575, a Phase 1 treatment for atopic dermatitis with data anticipated in the fourth quarter of 2026. The company held approximately $700 million in available liquidity as of December 31, 2025, following a $146.4 million net loss for the year.

Historically, AbCellera generated revenue by acting as a technology partner: since 2014 it started 104 partner-initiated antibody discovery programs, retaining downstream royalties and milestone payments as its partners advance drugs toward approval, with 19 molecules from its platform having reached the clinic. Since late 2023 the company has shifted focus toward its own internal pipeline, reducing new discovery partnerships while continuing obligations under existing multi-year agreements. In 2025 it completed a 130,000-square-foot clinical manufacturing facility in Vancouver, allowing it to control supply chain and manufacture drug substance in-house rather than relying on a contract manufacturing organization for early-phase trials. The company has also received CAD $475.6 million (US$347.9 million) in non-dilutive government financing from Canada and British Columbia since 2020, including CAD $300 million tied to an eight-year project supporting up to 17 internal programs through Phase 1 trials.

Show full overview

AbCellera's near-term investment case turns substantially on two early-stage binary readouts rather than diversified revenue: topline Phase 1/2 data for ABCL635 is expected in the third quarter of 2026 and Phase 1 data for ABCL575 in the fourth quarter, with two additional candidates, ABCL688 and ABCL386, not entering clinical trials until 2027. The 10-K notes the company does not anticipate generating sufficient revenue to achieve profitability until it either develops a drug independently or secures significant economic participation in a partner's approved product, leaving profitability contingent on outcomes still years away.

See also: Healthcare · Biotechnology

From AbCellera Biologics Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 16, 2026

Recent Developments — AbCellera Biologics Inc.

Latest news

Latest item Nov 16, 2026 · Generated 2026-11-17T11:52:23Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Feb 23, 202798d to earnings· next earnings call

Thesis

Rewards
Recent Analyst detected in news
Risks
Quality below floor (2.1 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-15.7
Mkt Cap$3.6B
EV/EBITDA-17.1
Profit Mgn-248.8%
ROE-17.3%
Rev Growth-76.3%
Beta1.59
DividendNone
Analysts with ratings18

Quality Signals

Piotroski F3/9

Options Flow

P/C1.56bearish
IV99%elevated

Material Events(8-K, last 90d)

  • 2026-06-05Item 5.02LOW
    Board appointed Victor Sandor as a new independent director effective June 1, 2026, serving until the next annual shareholder meeting. Routine board appointment; no departure or successor context involved.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Unprofitable operations — net margin -248.8%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Fcf Quality
0.0
Piotroski F
3.3
Moat
4.0
Current Ratio
5.0
Cash-burning: FCF -70% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
0.8
Value Rank
1.0
Quality Rank
3.3

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Obv
1.0
Volume
1.9
Macd
2.0
Ma Position
4.0
Rsi
7.5
Uptrend pullback (RSI 40) - buy opportunityVolume distribution (falling OBV)Above 200-day MA
GatesMomentum 3.3<4.5Executive change: officer departure/appointmentA.R:R 3.1 ≥ 1.5Insider activity: OKNEWS BOOST ANALYST 0.50EARNINGS PROXIMITY 98d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
40 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $10.76Resistance $13.86

Price Targets

$10
$16
A.Upside+46.0%
A.R:R3.1:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (2.1 < 4.0)
! momentum at 3.3 (below the engine's 4.5 threshold)

Earnings

B
B
B
M
3/4 beats
Next Earnings2027-02-23 (98d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ABCL stock a buy right now?

Sell if holding. Engine safety override at $11.12: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 1.56; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $10.44. Score 5.4/10, moderate confidence.

What is the ABCL stock price target?

Analyst target: $16.24 (+46.0% upside). Prior stop was $10.44. Stop-loss: $10.44.

What are the risks of investing in ABCL?

Quality below floor (2.1 < 4.0).

Is ABCL overvalued or undervalued?

AbCellera Biologics Inc. trades at a P/E of N/A (forward -15.7). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about ABCL?

18 analysts rate ABCL, with a consensus score of 4.1/5. 12 analysts publish price targets averaging $19.

What does AbCellera Biologics Inc. do?AbCellera Biologics is a clinical-stage biotechnology company developing antibody medicines, with two internal...

AbCellera Biologics is a clinical-stage biotechnology company developing antibody medicines, with two internal candidates in clinical trials - ABCL635 for vasomotor symptoms and ABCL575 for atopic dermatitis - alongside a portfolio of royalty and milestone stakes from more than 100 historical partner-initiated programs. The company reported a $146.4 million net loss in 2025 against approximately $700 million in available liquidity, and has shifted its business model from a discovery-services partner to a company building its own drug pipeline.

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · ASND (Ascendis Pharma A/S) · HALO (Halozyme Therapeutics, Inc.) · MGTX (MeiraGTx Holdings plc) · PHAT (Phathom Pharmaceuticals, Inc.)
Home › Stocks › ABCL

Latest news

Latest News

Fiscal.ai17h agoAnalyst
Benzinga23h agoAnalyst
Fiscal.ai4d ago
Benzinga6d agoAnalyst
Fiscal.ai7d agoAnalyst
Benzinga7d agoAnalyst
Fiscal.ai8d agoEarnings
Benzinga8d agoEarnings
Benzinga8d ago
Fiscal.ai12d ago
Fiscal.ai18d ago
Benzinga36d ago
Benzinga40d agoProduct
Benzinga49d ago
Benzinga54d agoAnalyst
Benzinga84d ago
Benzinga84d ago
Benzinga96d ago
Benzinga97d ago
Benzinga97d ago
Loading more...